Stay updated on CIN-107 in Primary Aldosteronism Clinical Trial
Sign up to get notified when there's something new on the CIN-107 in Primary Aldosteronism Clinical Trial page.

Latest updates to the CIN-107 in Primary Aldosteronism Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page footer revision/version label was updated from v3.5.2 to v3.5.3, indicating a site software/content delivery update rather than a change to the clinical study information.SummaryDifference0.1%

- Check24 days agoChange DetectedAdded Revision: v3.5.2; removed Revision: v3.5.0.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed.SummaryDifference0.1%

- Check60 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check67 days agoChange DetectedResults were posted for CIN-107 in adults with primary aldosteronism, including treatment-emergent adverse events, 12-week SBP/DBP changes, BP response rates, and pharmacodynamic marker responses (Part 1). Previously listed safety and efficacy data elements were removed from the page.SummaryDifference3%

- Check88 days agoChange DetectedAdded Revision: v3.4.2; removed the funding/operating-status notice and the previous Revision: v3.4.1.SummaryDifference0.4%

Stay in the know with updates to CIN-107 in Primary Aldosteronism Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CIN-107 in Primary Aldosteronism Clinical Trial page.